F182112 single-agent is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Shandong New Time Pharmaceutical Co., LTD (1) and Institute of Hematology & Blood Diseases Hospital, China (1). Registered phases: Phase 3 and Phase 1. Conditions studied include Relapsed or Refractory Multiple Myeloma (RRMM); Autoimmune Hemolytic Anemia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07579234 | A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗) Relapsed or Refractory Multiple Myeloma (RRMM) |
Phase 3 | Recruiting |
| NCT07816341 | Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia (ClinicalTrials.gov ↗) Autoimmune Hemolytic Anemia |
Phase 1 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Relapsed or Refractory Multiple Myeloma (RRMM) | 1 |
| Autoimmune Hemolytic Anemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Shandong New Time Pharmaceutical Co., LTD | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Register | F182112 single-agent trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how F182112 single-agent works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists F182112 single-agent (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.